A 12-week multicentre, randomised, double-blind, parallel group, Phase II pilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mg bid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtine citrate 400 mg bid (800 mg/d)
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest